'Dangerous' dementia drugs to be reviewed
Friday 20 June 2008
The prescribing of powerful anti-psychotic drugs to patients with dementia is to be reviewed immediately, ministers have said.
The announcement follows evidence that up to half of GPs are prescribing the drugs as a "chemical cosh" to subdue challenging patients, despite safety warnings issued four years ago. Ivan Lewis, a Health minister, ordered the review at the launch of a proposed national dementia strategy to improve care for the 570,000 sufferers in England.
Two drugs, risperidone and olanzapine, are widely used in treating schizophrenia but carry an increased risk of stroke in elderly patients. However, a recent survey of 355 GPs by BBC Radio 4 found more than half admitted prescribing them.
Mr Lewis said: "This first-ever national dementia strategy... will set out how we will improve the quality of life for people with dementia and their families, improve their quality of care, increase awareness and ensure earlier diagnosis and intervention."
Life & Style blogs
How psychopaths hide in plain sight – a psychological analysis of serial killer Dennis Rader
Majority of UK women don't bathe or take a shower daily
This is what it's like to be dead, according to a guy who died for a bit
How I rescued my brain: Psychologist David Roland rewired his thoughts following a stroke
Brit Awards 2015: Red carpet round up, from Paloma Faith to Ed Sheeran
- 1 Liam Gallagher brands Kanye West 'utter s**t' during BRIT Awards performance
- 2 Isis burns thousands of books and rare manuscripts from Mosul's libraries
- 3 People who sleep more than eight hours are more likely to have a stroke, research shows
- 5 Muslim women's rights campaigner writes heartfelt letter to girls thinking of joining Isis
£23000 - £26000 per annum: Recruitment Genius: This small, friendly, proactive...
£14500 - £22800 per annum: Recruitment Genius: This is a fantastic opportunity...
Negotiable: Recruitment Genius: A Software Developer is required to join a lea...
Excellent Salary: Austen Lloyd: A first rate opportunity to join a top ranking...